Close Menu

Quidel

New products and a more normal 2016-17 flu season could accelerate revenues for Quidel, the investment bank said.

Infectious disease product revenues fell 25 percent year over year, while women's health and gastrointestinal sales were flat.

The firm also reported a 7 percent increase in full-year revenues, slightly ahead of the consensus analysts' estimate.

The firm's preliminary revenues were lower than expected and led to analyst downgrades and a drop in early trade.

The bank downgraded Quidel's shares to market perform and trimmed its Q4 revenue forecast due to a mild flu season.

The increased revenues were driven in part by increased sales of Sofia immunoassay products and new products. 

A number of firms now have FDA-approved Group A Strep assays, but end users may be hesitant to adopt them until Infectious Disease Society of America guidelines are updated.

The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.

Sales of Sofia rapid immunoassay platforms and diagnostic kits led the increase in revenues.

Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.